Le Cong

Rootpath Genomics, Inc. engages in the provision of biotechnology services. It develops personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. The company was founded by Xi Chen, Le Cong, Yinqing Li, Cheryl Cui, and Ely Porter in 2017 and is headquartered in Cambridge, MA.

Rootpath Genomics, Inc. engages in the provision of biotechnology services. It develops personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. The company was founded by Xi Chen, Le Cong, Yinqing Li, Cheryl Cui, and Ely Porter in 2017 and is headquartered in Cambridge, MA.

Rootpath Genomics, Inc. engages in the provision of biotechnology services. It develops personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. The company was founded by Xi Chen, Le Cong, Yinqing Li, Cheryl Cui, and Ely Porter in 2017 and is headquartered in Cambridge, MA.

Rootpath Genomics, Inc. engages in the provision of biotechnology services. It develops personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. The company was founded by Xi Chen, Le Cong, Yinqing Li, Cheryl Cui, and Ely Porter in 2017 and is headquartered in Cambridge, MA.

Rootpath Genomics, Inc. engages in the provision of biotechnology services. It develops personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. The company was founded by Xi Chen, Le Cong, Yinqing Li, Cheryl Cui, and Ely Porter in 2017 and is headquartered in Cambridge, MA.